Detailed financial statements for Lunai Bioworks Inc. (LNAI): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | 892.52% |
| Return on Invested Capital | 120.87% |
| Return on Assets | -1300.98% |
| Gross Margin | -360.71% |
| Operating Margin | -46991.97% |
| Net Margin | -612568.11% |
Financial Health
| Debt / Equity | -0.15 |
| Current Ratio | 0.19 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -97.60 |
Related companies: ADAP · ANL · APLM · BLRX · ERNA · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of LNAI: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks